^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | trastuzumab vedotin (MRG002) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
Excerpt:
...Patients with HER2-positive breast cancer confirmed by central laboratory and with evidence of liver metastasis by imaging; 5....
Trial ID:
Source:
Title:
271P - First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Published date:
09/13/2021
Excerpt:
The starting dose of MRG002 was 0.3 mg/kg, followed by 0.6, 1.2, 1.8, 2.2, 2.6, and 3.0 mg/kg, all pts with BC and GC had HER2+ per CAP guidelines….Of these 21 pts, 16 pts were HER2+ breast cancer, 8 PR, 5 SD, and ORR was 50% (8/16), DCR was 81%(13/16).
